A New Approach To Treat And Prevent Covid-19

As SARS-CoV-2 variants grow in type and frequency, Covid-19 researchers are on the hunt for parts of the virus that remain consistent across variants in order to create Covid-19 treatments that work for multiple strains of the virus. This is the third in a series discussing these potential Achilles’ heels for Covid-19. Read more from this series in part one and part two. Antibodies have been at the forefront in the search for drugs to prevent and treat Covid-19. Combination antibodies effectively reduce infection length if given early enough and prevent infection for those exposed. However, there are some inherent difficulties with antibodies as drugs. They are relatively large molecules that are expensive to produce. Additionally,  SARS-CoV-2 mutates to resist single and, in some cases, to double-antibody cocktails.  Here we describe a new approach to the same end using antibodies derived from camelids, a biological family which includes mammals such as camels, llamas, and alpacas. Camelid-derived antibodies lack a light chain and are composed of two identical heavy chains. These unique heavy-chain antibodies are also known as nanobodies. Camelid nanobodies are less than a quarter of the size of human antibodies. They are more stable, more simply modified, and less inexpensive than traditional monoclonal antibody drugs. These unique qualities have prompted researchers to develop camelid-derived nanobody drugs for Covid-19. Read the full article on Forbes.
© William A. Haseltine, PhD. All Rights Reserved.